{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:22:31Z","timestamp":1783092151582,"version":"3.54.6"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Botulinum neurotoxins (BoNTs) are the bacterial proteins responsible for the flaccid paralysis and lethal effects of botulism. They act by inhibiting neurotransmitter release, primarily at peripheral cholinergic nerve terminals, and have traditionally been classified into seven serotypes, designated with letters A through G. Over a long history of investigation, scientists and physicians have learned to harness the selectivity and potency of these neurotoxins to advance therapeutic applications. These advances have come by leveraging the basic science understanding of how the BoNT\u2019s work. The BoNTs are typically produced as inactive single-chain proteins of 150\u00a0kDa that can be proteolytically activated to form a 50\u00a0kDa light chain (LC) and 100\u00a0kDa heavy chain (HC) that remain linked by a disulfide bond. The BoNTs act through a multi-step mechanism in which the HC mediates receptor binding and translocation of the LC into the neuronal cell cytosol. The LC is a zinc endopeptidase and each BoNT serotype cleaves a unique and specific bond within the three-protein soluble\n                    <jats:italic>N<\/jats:italic>\n                    -ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. In the late 1990s, I had the opportunity to help visualize the atomic structure of this formidable molecule, a story I share to honor the legacy of Hans Bigalke, whose work set the stage for new careers and discoveries in BoNT research and medicine.\n                  <\/jats:p>","DOI":"10.1007\/s00702-025-03048-1","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:21:32Z","timestamp":1762431692000},"page":"935-938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elucidating the crystal structure of botulinum neurotoxin type A: a personal remembrance"],"prefix":"10.1007","volume":"133","author":[{"given":"D. Borden","family":"Lacy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"3048_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12732","volume":"505","author":"RM Benoit","year":"2014","unstructured":"Benoit RM, Frey D, Hilbert M, Kevenaar JT, Wieser MM, Stirnimann CU, McMillan D, Ceska T, Lebon F, Jaussi R, Steinmetz MO, Schertler GFX, Hoogenraad CC, Capitani G, Kammerer RA (2014) Structural basis for recognition of synaptic vesicle protein 2\u00a0C by botulinum neurotoxin A. Nature 505:108\u2013111","journal-title":"Nature"},{"key":"3048_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00499155","volume":"312","author":"H Bigalke","year":"1980","unstructured":"Bigalke H, Habermann E (1980) Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol 312:255\u2013263","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3048_CR3","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.3390\/toxins7124855","volume":"7","author":"H Bigalke","year":"2015","unstructured":"Bigalke H, Rummel A (2015) Botulinum neurotoxins: qualitative and quantitative analysis using the mouse phrenic nerve hemidiaphragm assay (MPN). Toxins 7:4895\u20134905","journal-title":"Toxins"},{"key":"3048_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF00508058","volume":"303","author":"H Bigalke","year":"1978","unstructured":"Bigalke H, Dimpfel W, Habermann E (1978) Suppression of 3H-acetylcholine release from primary nerve cell cultures by tetanus and botulinum-A toxin. Naunyn Schmiedebergs Arch Pharmacol 303:133\u2013138","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3048_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF00505308","volume":"316","author":"H Bigalke","year":"1981","unstructured":"Bigalke H, Ahnert-Hilger G, Habermann E (1981) Tetanus toxin and botulinum A toxin inhibit acetylcholine release from but not calcium uptake into brain tissue. Naunyn Schmiedebergs Arch Pharmacol 316:143\u2013148","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3048_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/0041-0101(86)90133-9","volume":"24","author":"H Bigalke","year":"1986","unstructured":"Bigalke H, M\u00fcller H, Dreyer F (1986) Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure. Toxicon 24:1065\u20131074","journal-title":"Toxicon"},{"key":"3048_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nature03123","volume":"432","author":"MA Breidenbach","year":"2004","unstructured":"Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432:925\u2013929","journal-title":"Nature"},{"key":"3048_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1126\/science.1214270","volume":"335","author":"S Gu","year":"2012","unstructured":"Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977\u2013981","journal-title":"Science"},{"key":"3048_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00500299","volume":"311","author":"E Habermann","year":"1980","unstructured":"Habermann E, Dreyer F, Bigalke H (1980) Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn Schmiedebergs Arch Pharmacol 311:33\u201340","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3048_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00505307","volume":"316","author":"E Habermann","year":"1981","unstructured":"Habermann E, Bigalke H, Heller I (1981) Inhibition of synaptosomal choline uptake by tetanus and botulinum A toxin. Partial dissociation of fixation and effect of tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol 316:135\u2013142","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"3048_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/febs.16964","volume":"291","author":"S Ko\u0161enina","year":"2024","unstructured":"Ko\u0161enina S, \u0160kerlov\u00e1 J, Zhang S, Dong M, Stenmark P (2024) The cryo-EM structure of the BoNT\/Wo-NTNH complex reveals two immunoglobulin-like domains. FEBS J 291(4):676\u2013689","journal-title":"FEBS J"},{"key":"3048_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/prep.1997.0772","volume":"11","author":"DB Lacy","year":"1997","unstructured":"Lacy DB, Stevens RC (1997) Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Protein Expr Purif 11:195\u2013200","journal-title":"Protein Expr Purif"},{"key":"3048_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1006\/jmbi.1999.2945","volume":"291","author":"DB Lacy","year":"1999","unstructured":"Lacy DB, Stevens RC (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291:1091\u20131104","journal-title":"J Mol Biol"},{"key":"3048_CR14","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/2338","volume":"5","author":"DB Lacy","year":"1998","unstructured":"Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898\u2013902","journal-title":"Nat Struct Biol"},{"key":"3048_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0304-3940(89)90828-8","volume":"107","author":"P Marxen","year":"1989","unstructured":"Marxen P, Bigalke H (1989) Tetanus toxin: inhibitory action in chromaffin cells is initiated by specified types of gangliosides and promoted in low ionic strength solution. Neurosci Lett 107:261\u2013266","journal-title":"Neurosci Lett"},{"key":"3048_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/0041-0101(89)90097-4","volume":"27","author":"P Marxen","year":"1989","unstructured":"Marxen P, Fuhrmann U, Bigalke H (1989) Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells. Toxicon 27:849\u2013859","journal-title":"Toxicon"},{"key":"3048_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/0022-2836(91)90581-P","volume":"222","author":"RC Stevens","year":"1991","unstructured":"Stevens RC, Evenson ML, Tepp W, DasGupta, BR (1991) Crystallization and preliminary X-ray analysis of botulinum neurotoxin type A. J Mol Biol 222:877\u2013880","journal-title":"J Mol Biol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03048-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03048-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03048-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:59:16Z","timestamp":1783090756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03048-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3048"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03048-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}